ConductScience.org, home

Paper41396112

Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome.

Uslu E and 6 others. Sarcoidosis Vasc Diffuse Lung Dis, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome. Papers, record 41396112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41396112

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome.
PubMed
Journal
Sarcoidosis Vasc Diffuse Lung Dis
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-01-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1296259682018 update of the EULAR recommendations for the management of Behçet's syndrome.Ann Rheum Dis2018https://conductscience.org/library/papers/29625968PubMed
27923750Cyclosporine: mechanisms of action and toxicity.Cleve Clin J Med1994https://conductscience.org/library/papers/7923750PubMed
331976619Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.Int J Rheum Dis2020https://conductscience.org/library/papers/31976619PubMed
410528040Behçet's disease.N Engl J Med1999https://conductscience.org/library/papers/10528040PubMed
531139195Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils.Front Immunol2019https://conductscience.org/library/papers/31139195PubMed
622210555Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients.Medicine (Baltimore)2012https://conductscience.org/library/papers/22210555PubMed
727886800Behçet's disease: How to diagnose and treat vascular involvement.Best Pract Res Clin Rheumatol2016https://conductscience.org/library/papers/27886800PubMed
89125262Azathioprine in Behcet's syndrome: effects on long-term prognosis.Arthritis Rheum1997https://conductscience.org/library/papers/9125262PubMed
937385325Infliximab for vascular involvement in Behçet's syndrome.Clin Immunol2023https://conductscience.org/library/papers/37385325PubMed
1010410282Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A.Clin Exp Rheumatol1999https://conductscience.org/library/papers/10410282PubMed
112356556Cyclosporin treatment in rapidly progressive pulmonary thromboembolic Behçet's disease.Thorax1990https://conductscience.org/library/papers/2356556PubMed
1210759951Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease.Histopathology2000https://conductscience.org/library/papers/10759951PubMed
1321699532Mycophenolate sodium in the treatment of mucocutaneous Behcet's diseases.Int J Dermatol2011https://conductscience.org/library/papers/21699532PubMed
1412544711The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.Medicine (Baltimore)2003https://conductscience.org/library/papers/12544711PubMed
1521968239Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases.Clin Exp Rheumatol2011https://conductscience.org/library/papers/21968239PubMed
1611752821Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease.Dermatology2001https://conductscience.org/library/papers/11752821PubMed
1727310969Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.Medicine (Baltimore)2016https://conductscience.org/library/papers/27310969PubMed
1829631062Behçet's disease: New insights into pathophysiology, clinical features and treatment options.Autoimmun Rev2018https://conductscience.org/library/papers/29631062PubMed
1914673387Behçet syndrome.Curr Opin Rheumatol2004https://conductscience.org/library/papers/14673387PubMed
2026190564Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment.Semin Arthritis Rheum2015https://conductscience.org/library/papers/26190564PubMed

See all 34 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41396112

GET https://conductscience.org/api/papers/v1/41396112/references?page=2